A Randomized Phase II Trial assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512502-26-00

Acronym

BL.13

Enrollment

Registered

2024-04-03

Start date

2019-11-06

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-invasive bladder cancer

Brief summary

Disease-free survival. From randomization to either recurrent (local or distant) bladder cancer, a new primary bladder cancer or death from any cause

Detailed description

Locoregional Control Rate (LCR) Bladder-intact Disease-Free Survival Overall Survival Evaluable for Adverse Events Evaluable for Quality of Life Assessment Evaluable for Economic Analysis

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease-free survival. From randomization to either recurrent (local or distant) bladder cancer, a new primary bladder cancer or death from any cause	—

Secondary

Measure	Time frame
Locoregional Control Rate (LCR) Bladder-intact Disease-Free Survival Overall Survival Evaluable for Adverse Events Evaluable for Quality of Life Assessment Evaluable for Economic Analysis	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026